These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 10456888

  • 1. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
    Nussbaum G, Anandasabapathy S, Mukherjee J, Fan M, Casadevall A, Scharff MD.
    Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
    [Abstract] [Full Text] [Related]

  • 2. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Pirofski L, Lui R, DeShaw M, Kressel AB, Zhong Z.
    Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
    [Abstract] [Full Text] [Related]

  • 3. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
    Casadevall A, DeShaw M, Fan M, Dromer F, Kozel TR, Pirofski LA.
    Infect Immun; 1994 Sep; 62(9):3864-72. PubMed ID: 8063403
    [Abstract] [Full Text] [Related]

  • 4. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    Casadevall A, Mukherjee J, Devi SJ, Schneerson R, Robbins JB, Scharff MD.
    J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.
    Maitta RW, Datta K, Lees A, Belouski SS, Pirofski LA.
    Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097
    [Abstract] [Full Text] [Related]

  • 6. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.
    Mukherjee J, Casadevall A, Scharff MD.
    J Exp Med; 1993 Apr 01; 177(4):1105-16. PubMed ID: 8459205
    [Abstract] [Full Text] [Related]

  • 7. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis.
    Fleuridor R, Zhong Z, Pirofski L.
    J Infect Dis; 1998 Oct 01; 178(4):1213-6. PubMed ID: 9806064
    [Abstract] [Full Text] [Related]

  • 8. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
    Beenhouwer DO, May RJ, Valadon P, Scharff MD.
    J Immunol; 2002 Dec 15; 169(12):6992-9. PubMed ID: 12471134
    [Abstract] [Full Text] [Related]

  • 9. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
    Devi SJ, Schneerson R, Egan W, Ulrich TJ, Bryla D, Robbins JB, Bennett JE.
    Infect Immun; 1991 Oct 15; 59(10):3700-7. PubMed ID: 1716613
    [Abstract] [Full Text] [Related]

  • 10. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
    Valadon P, Nussbaum G, Oh J, Scharff MD.
    J Immunol; 1998 Aug 15; 161(4):1829-36. PubMed ID: 9712050
    [Abstract] [Full Text] [Related]

  • 11. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
    Maitta RW, Datta K, Chang Q, Luo RX, Witover B, Subramaniam K, Pirofski LA.
    Infect Immun; 2004 Aug 15; 72(8):4810-8. PubMed ID: 15271943
    [Abstract] [Full Text] [Related]

  • 12. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
    Mukherjee J, Feldmesser M, Scharff MD, Casadevall A.
    Antimicrob Agents Chemother; 1995 Jul 15; 39(7):1398-405. PubMed ID: 7492075
    [Abstract] [Full Text] [Related]

  • 13. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
    Fleuridor R, Lees A, Pirofski L.
    J Immunol; 2001 Jan 15; 166(2):1087-96. PubMed ID: 11145689
    [Abstract] [Full Text] [Related]

  • 14. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.
    Mukherjee J, Scharff MD, Casadevall A.
    Infect Immun; 1995 Sep 15; 63(9):3353-9. PubMed ID: 7642262
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
    Maitta RW, Datta K, Pirofski LA.
    Vaccine; 2004 Sep 28; 22(29-30):4062-8. PubMed ID: 15364457
    [Abstract] [Full Text] [Related]

  • 16. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
    Mukherjee J, Kozel TR, Casadevall A.
    J Immunol; 1998 Oct 01; 161(7):3557-68. PubMed ID: 9759877
    [Abstract] [Full Text] [Related]

  • 17. The function of conserved amino acids in or near the complementarity determining regions for related antibodies to Cryptococcus neoformans glucuronoxylomannan.
    Nakouzi A, Casadevall A.
    Mol Immunol; 2003 Oct 01; 40(6):351-61. PubMed ID: 14522016
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
    Cleare W, Cherniak R, Casadevall A.
    Infect Immun; 1999 Jun 01; 67(6):3096-107. PubMed ID: 10338526
    [Abstract] [Full Text] [Related]

  • 19. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
    Mukherjee S, Lee S, Mukherjee J, Scharff MD, Casadevall A.
    Infect Immun; 1994 Mar 01; 62(3):1079-88. PubMed ID: 8112842
    [Abstract] [Full Text] [Related]

  • 20. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
    May RJ, Beenhouwer DO, Scharff MD.
    J Immunol; 2003 Nov 01; 171(9):4905-12. PubMed ID: 14568972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.